Imricor Medical Systems Management

Management criteria checks 3/4

Imricor Medical Systems' CEO is Steve Wedan, appointed in May 2006, has a tenure of 18.17 years. total yearly compensation is $464.90K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.51% of the company’s shares, worth A$2.95M. The average tenure of the management team and the board of directors is 6 years and 7.5 years respectively.

Key information

Steve Wedan

Chief executive officer

US$464.9k

Total compensation

CEO salary percentage	100.0%
CEO tenure	18.2yrs
CEO ownership	2.5%
Management average tenure	6yrs
Board average tenure	7.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Wedan's remuneration changed compared to Imricor Medical Systems's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$465k	US$465k	-US$23m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$465k	US$465k	-US$17m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$20m
Dec 31 2021	US$577k	US$464k	-US$20m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$565k	US$452k	-US$12m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$349k	US$349k	-US$13m

Compensation vs Market: Steve's total compensation ($USD464.90K) is above average for companies of similar size in the Australian market ($USD292.71K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Wedan (55 yo)

18.2yrs

Tenure

US$464,900

Compensation

Mr. Steven Wedan, also known as Steve, has been the Chief Executive Officer, President and Director of Imricor Medical Systems Inc. since May 23, 2006 and serves as its Executive Chairman. Mr. Wedan has me...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Wedan	President	18.2yrs	US$464.90k	2.51% $ 2.9m
Jonathon Gut	CFO & VP of Finance	2yrs	US$259.38k	no data
Gregg Stenzel	Chief Operating Officer	17.5yrs	US$315.00k	no data
Greg Englehardt	Senior Director of Sales	6.5yrs	no data	no data
Nick Twohy	Vice President of Marketing & Business Development	5.5yrs	no data	no data
Kobe Lizheng	Company Secretary & Local Agent	5.3yrs	no data	no data

6.0yrs

Average Tenure

Experienced Management: IMR's management team is seasoned and experienced (6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Steven Wedan	President	18.2yrs	US$464.90k	2.51% $ 2.9m
Anita Messal	Independent Non-Executive Director	3.3yrs	US$75.00k	0.17% $ 204.8k
Peter McGregor	Independent Non-Executive Director	5.2yrs	US$80.00k	0.43% $ 506.4k
Mark Tibbles	Independent Deputy Chairman & Lead Independent Director	9.8yrs	US$80.00k	3.07% $ 3.6m

7.5yrs

Average Tenure

56yo

Average Age

Experienced Board: IMR's board of directors are considered experienced (7.5 years average tenure).

Imricor Medical Systems Management

Management criteria checks 3/4

Key information

Recent management updates

Independent Non-Executive Director recently bought AU$73k worth of stock

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Insufficient new directors

Key Executive recently bought AU$195k worth of stock

President recently bought AU$76k worth of stock

President recently bought AU$76k worth of stock

Recent updates

New major risk - Revenue and earnings growth

Independent Non-Executive Director recently bought AU$73k worth of stock

Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million.

Insufficient new directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022)

Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Revenue and earnings growth

Imricor Medical Systems, Inc. has filed a Follow-on Equity Offering in the amount of AUD 15 million.

First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022)

New major risk - Revenue and earnings growth

Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding

Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023

Imricor Medical Systems, Inc. announced that it has received AUD 1.457143 million in funding

New minor risk - Share price stability

Key Executive recently bought AU$195k worth of stock

Full year 2022 earnings released

Imricor Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 22, 2023

Imricor Medical Systems, Inc. Receives IDE Approval from US FDA

Forecast to breakeven in 2025

Imricor Medical Systems, Inc. Receives the First of Two Required Approvals to Commence the Vision-MR Ablation of VT or VISABL-VT Clinical Trial

Imricor Medical Systems, Inc. announced that it expects to receive $5 million in funding from KAHR Foundation

President recently bought AU$76k worth of stock

President recently bought AU$76k worth of stock

Imricor Medical Systems, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Imricor Medical Systems, Inc. Submits Application for Approval to Commence A Real-Time iCMR-Guided Ventricular Tachycardia (VT) Ablation Clinical Trial

Imricor Medical Systems, Inc. announced that it has received AUD 2.947049 million in funding

First half 2022 earnings released: US$0.068 loss per share (vs US$0.079 loss in 1H 2021)

Imricor Medical Systems, Inc. to Report First Half, 2022 Results on Aug 25, 2022

Imricor Medical Systems, Inc. to Report Q4, 2022 Results on Jul 28, 2022

Imricor Medical Systems, Inc. Completes its Preclinical Work to Support Submission for Approval to Initiate VT Clinical Trial in Europe

Imricor Medical Systems, Inc., Annual General Meeting, May 03, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Imricor Medical Systems, Inc. Announces Executive Changes

Imricor Medical Systems, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Imricor Medical Systems, Inc. Files Application for an Investigational Device Exemption from US Food and Drug Administration

First half 2021 earnings released: US$0.079 loss per share (vs US$0.056 loss in 1H 2020)

No longer forecast to breakeven

Non-Executive Director has left the company

Imricor Medical Systems, Inc. Announces Board Changes

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.22 loss in FY 2019)

Revenue beats expectations

New 90-day low: AU$2.17

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Imricor Medical Systems, Inc. Appoints Gregg Stenzel as COO

Imricor Signs Supply and Sales Agreement with Osypka

Imricor Medical Systems, Inc. Signs New Purchase Agreement

Imricor Medical Systems, Inc. (ASX:IMR) signed an agreement to acquire Schleswig-Holstein University Medical Centre in Germany.

Imricor Medical Systems, Inc. to Commence Clinical Procedures After Receiving Ethics Committee Approval to Use Isuite Software

Imricor Awards National Institutes of Health Contract

Imricor Medical Systems, Inc. Signs Purchase Agreement with MUMC

Leipzig Heart Centre Signs Purchase Agreement with Imricor Medical Systems

Earnings released

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Aug 25, 2020

Imricor Medical Systems, Inc. to Report Q2, 2020 Results on Jul 29, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age